Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Plunging Today

By Keith Speights – Nov 5, 2021 at 11:40AM

Key Points

  • Pfizer announced positive results from a phase 3 study of its COVID-19 pill.
  • Investors are concerned that the pill could hurt demand for BioNTech's COVID vaccine.
  • Those fears could be overblown, however.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for Pfizer was seen as potentially bad news for BioNTech.

What happened

Shares of BioNTech (BNTX 0.94%) were plunging 19.8% as of 11:12 a.m. EDT on Friday. The steep decline came after Pfizer (PFE 0.84%) announced positive results from a late-stage study of its experimental COVID-19 pill Paxlovid. 

Pfizer reported that the risk of hospitalization or death was reduced by 89% in high-risk adults receiving Paxlovid compared to individuals receiving placebo. Through day 28 of the study, there were no deaths in patients who received the COVID pill compared to 10 deaths in the placebo group.

A capsule pill with COVID-19 on it.

Image source: Getty Images.

So what

Why would Pfizer's positive results weigh so heavily on BioNTech's shares? Investors appear to believe that the availability of another highly effective COVID pill could hurt the demand for vaccines. Merck and its partner, Ridgeback Biotherapeutics, announced positive results for their COVID pill last month.

BioNTech wasn't the only vaccine stock that took a hit with Pfizer's update. Shares of Moderna and Novavax were also sinking today. The conventional wisdom that COVID pills could hurt vaccine sales might not be on point, though.

It seems unlikely that governments across the world will retreat from their vaccination strategies just because oral therapies are available. Also, the price tag of the COVID pills will be significantly higher than the costs of vaccine doses. For example, the U.S. government is paying around $700 per treatment course for Merck's COVID pill. By comparison, the cost for one dose of the Pfizer-BioNTech vaccine is only $19.50. 

Now what

Pfizer plans to file for Emergency Use Authorization of Paxlovid soon. Even if it wins authorization (which seems likely), BioNTech's prospects should be solid. Investors can look forward to the company potentially providing some good news of its own when BioNTech announces its third-quarter results next week.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.